In patients with a history of idiopathic venous thromboembolism (VTE), is plasma D-dimer helpful in evaluating the risk of recurrence to determine whether oral anticoagulation therapy (OAT) is appropriate beyond the standard 3-6 months of therapy?
Methodology
The relevant literature was obtained through a PubMed search using the following keywords simultaneously: venous thromboembolism, anticoagulation, D-dimer, and duration. Inclusion criteria for articles were that they be randomized control trials, prospective cohort studies, or meta-analyses, published over the past 12 years, and in English.
Evidence Summary
Several studies supported the above recommendations. A prospective 21-month study that included 599 subjects with a previous idiopathic VTE episode showed that a negative D-dimer measured at one month following therapy cessation had a high negative predictive value (over 92%) for VTE recurrence.
1 A second prospective study involving 396 subjects showed a similar result with a negative predictive value over 95%.
2 Furthermore, in a randomized controlled trial (the PROLONG study), patients with an elevated D-dimer result one month after stopping OAT had a significantly increased risk of VTE recurrence. 3 The authors recommended that OAT be restarted in individuals with an elevated D-dimer.
A 2003 prospective cohort study of 610 adults addressed the differing levels of risk based on the magnitude of an abnormal D-dimer. 4 The results showed a significantly increased risk of VTE at two-years post-OAT cessation for individuals with a D-dimer level of more than 750 ng/ml measured three weeks following cessation of OAT compared with those with a level of less than 250 ng/ml (11.5% vs 3.7%). A meta-analysis of randomized controlled trials and prospective cohort studies demonstrated an almost 3-fold recurrence risk increase when the Ddimer is positive following at least three months of anticoagulation.
5 A meta-analysis of four studies and over 1500 patients found a two-fold increase in risk of VTE recurrence during the follow-up period when a D-dimer level was abnormal.
6 Cosmi et al. 7 published a prospective cohort study that showed similar results and that an abnormal D-dimer was an independent risk factor for VTE recurrence.
An extension to the PROLONG study showed that there was a significant reduction in VTE recurrence up to approximately 2.5 years with a negative D-dimer. 8 There also was a significant decrease in VTE risk if OAT is restarted and continued during this period. This study also showed that the risk of a major bleeding episode due to OAT is greater than the risk of recurrent VTE, which needs to be considered carefully in each clinical situation. A prospective cohort study from 2008 followed 861 patients and showed elevated D-dimer to be an independent risk factor for recurrent VTE. 9 The PROLONG II study found that a persistently negative D-dimer for one year after cessation of OAT signified an almost 10-fold decrease in the relative risk of VTE recurrence within a mean of 10-11 months following OAT cessation.
10 Finally, a recently published study of 1010 patients with either idiopathic or low-risk factor VTE showed that serial measurement of a D-dimer both at the time of stopping OAT and at intervals for the three months following cessation was effective at identifying patients at low risk of recurrence.
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Conclusions
Evidence supports the use of D-dimer testing to determine the risk of VTE recurrence in patients with first episode of idiopathic VTE when OAT is discontinued following the standard 3-6 months of therapy. Based on the studies reviewed, it is reasonable that OAT be discontinued after 3-6 months to be followed-up with D-dimer testing at a one-month interval. An elevated Ddimer at that time raises significant concern for recurrence, prompting the physician and patient to weigh the risks and benefits of restarting OAT. There are unfortunately few trials that compare the risk of life-threatening VTE to risk of a life-threatening bleeding episode, therefore, more data on the comparative risk of a life-threatening OAT bleeding event during prolonged treatment for VTE should be collected before determining the final OAT treatment period. From the available data at this time, it is reasonable to use a non-elevated D-dimer result one month following the standard treatment period for idiopathic VTE to identify low-risk patients in whom OAT should not be resumed. Keywords: venous thromboembolism, anticoagulants, D-dimer, therapy
